Journal article
Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation
Cancer gene therapy, v 13(10), pp 969-974
Oct 2006
PMID: 16763607
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
In vivo
electroporation has been used to efficiently deliver drugs and ‘therapeutic’ genes to tumors, including melanoma lesions. This study reports on the effect of intratumoral delivery of an optimized DNA plasmid expressing interleukin-15 (pIL-15) on established murine melanoma tumors. IL-15 has been demonstrated to have a pivotal role in the function of memory CD8+ T cells and natural killer cells, which are critical for tumor immunosurveillance. In this study, C57BL/6 mice were injected with B16.F10 melanoma cells and randomized into different experimental groups: untreated (P−V−E−), treated with pIL-15 (P+) or backbone plasmid (V+), with or without electroporation (E+ or E−). Treatment was performed intratumorally with 50
μg
of plasmid on days 0, 4 and 7 and tumor volume/size, tumor regression and long-term survival were measured. At day 100 after initiation of treatment, the percentage of mice surviving with complete tumor regression in the P−V+E+, P+V−E−, P+V−E+ and P−V−E− treatment groups were 0, 12.5, 37.5 and 0%, respectively. These results demonstrate the ability of pIL-15 to mediate B16 melanoma regression, with the effect being significantly enhanced by electroporative delivery. This is the first description of the ability of a naked DNA plasmid expressing IL-15 to alone mediate complete regression of B16 melanoma tumors and underscores the potential clinical use of these plasmids for the treatment of malignant tumors when delivered with
in vivo
electroporation.
Metrics
Details
- Title
- Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation
- Creators
- K E Ugen - Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USAM A Kutzler - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USAB Marrero - Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USAJ Westover - Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USAD Coppola - Department of Pathology and Laboratory Medicine, University of South Florida College of Medicine, Tampa, FL, USAD B Weiner - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USAR Heller - Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USA
- Publication Details
- Cancer gene therapy, v 13(10), pp 969-974
- Publisher
- Springer Nature
- Grant note
- R01 CA122518-01A2 || CA / National Cancer Institute : NCI
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000240458800008
- Scopus ID
- 2-s2.0-33748571952
- Other Identifier
- 991014878049204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Biotechnology & Applied Microbiology
- Genetics & Heredity
- Medicine, Research & Experimental
- Oncology